Boston, MA 10/09/2014 (wallstreetpr) – Bio-pharmaceutical firm Arrowhead Research Corp (NASDAQ:ARWR) showcased much awaited data and results it has generated from its Phase 2 clinical study of drug candidate ARC-520 on 8th October. The disappointing data crashed the price of the company stock by nearly 43.8 percent. The drug maker indicated that it would be presenting the findings of the clinical test for peer review during the 2014 American Association for the Study of Liver Diseases Liver Conference, scheduled to be held in Boston during the week of 7th to 11th November. While investors expressed their disappointment with the phase 2 findings, company President and Chief Executive Officer Christopher Anzalone, Ph.D. expressed hope that the phase-2 data would form the foundation for finding a lasting cure to treat HBV.
Application networking technology and solutions provider A10 Networks Inc (NYSE:ATEN) announced the preliminary revenue numbers from its third quarter operations which ended on 30th September. The tech firm has indicated that its 3Q14 revenue might come in the range of $43.0 million to $43.5 million. These revenue numbers were well below the previously provided company outlook of $48.0 million to $50.0 million. In his comments to the press post the announcement, company CEO and President Lee Chen explained that the weakness the firm witnessed in its American operations leading to longer sales cycles was one of the key reasons for the weak revenue results. The stock was down 42.4 percent yesterday due to this reason.
Cloud-based software solutions provider Liquid Holdings Group Inc (NASDAQ:LIQD) announced on 8th October that it has rolled out its beta version of mobile application called “LiquidMobile” to choice customers. It indicated that the roll out started earlier in October. The positive news failed to enthuse the markets. The investors fled the stock resulting in 24.6 percent dip in the share price of the stock.